EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Phase 3b Extension Study MT ‐1186‐ A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

Angela Genge, Jeffrey Rothstein iD, Shari De Silva, Lorne Zinman iD, Marvin Chum iD, Adriano Chiò iD, Gen Sobue, Masashi Aoki, Hiide Yoshino, Manabu Doyu, Daniel Selness, Vesna Todorovic und 6 weitere

Muscle & Nerve · 2026

DOI: 10.1002/mus.70120 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Angela Genge und 17 weiteren Autor:innen. Beteiligte Einrichtung: Montreal Neurological Institute-Hospital, Montreal, Canada. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Edaravone, Free Radical Scavengers, Antipyrine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tanabe Pharma America, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is currently approved in the US for treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed that IV edaravone slows physical functional decline. Study MT‐1186‐A04 continued to examine the efficacy and safety of investigational once daily and approved on/off dosing of edaravone oral suspension in patients with ALS.

Methods

Study MT‐1186‐A04 (NCT05151471) was a phase 3b, multicenter, randomized, double‐blind, parallel group extension study for up to an additional 48 weeks following 48‐week Study MT‐1186‐A02 that randomized patients to investigational once daily or approved 105‐mg on/off dosing of edaravone oral suspension. Patients who met Study MT‐1186‐A04 eligibility criteria, including Study MT‐1186‐A02 completion, continued in the same treatment regimen as Study MT‐1186‐A02. The primary efficacy endpoint for MT‐1186‐A04 was time from randomization in Study MT‐1186‐A02 to a ≥ 12‐point decrease in ALS Functional Rating Scale‐Revised (ALSFRS‐R) or death, whichever happened first.

Results

Over 96 weeks, including Study MT‐1186‐A02, daily dosing did not show a statistically significant difference vs. approved on/off dosing for the primary endpoint ( p = 0.78). Edaravone oral suspension was well tolerated, and no new safety concerns were identified in either group.

Discussion

Similar to Study MT‐1186‐A02, once daily edaravone oral suspension in extension Study MT‐1186‐A04 did not show superiority in terms of the primary efficacy endpoint, but had equivalent efficacy, safety, and tolerability, compared with the approved On/Off regimen. The results reinforce the appropriateness of the approved dosing regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisEdaravoneFree Radical ScavengersAntipyrineHumansMaleMiddle AgedDouble-Blind MethodFemaleAgedTreatment OutcomeAdministration, OralAdultSuspensions

Stichwörter der Autor:innen

amyotrophic lateral sclerosisclinical trialedaravoneefficacysafety

Substanzen

EdaravoneFree Radical ScavengersSuspensionsAntipyrine

Autor:innen und Institutionen

  • Montreal Neurological Institute-Hospital, Montreal, Canada.
  • Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
  • Woodland Research Northwest, Rogers, Arkansas, USA.
  • Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
  • McMaster University Health Sciences Centre, Hamilton, Ontario, Canada.
  • Università degli Studi di Torino, Centro Regionale Esperto per la Sclerosi Laterale Amiotrofica (CRESLA), Turino, Italy.

ORCID-Profile: Jeffrey Rothstein, Lorne Zinman, Marvin Chum, Adriano Chiò, Fumihiro Takahashi, Stephen Apple

Förderung

  • Tanabe Pharma America, Inc.

Zitieren

APA

Genge, A., Rothstein, J., De Silva, S., Zinman, L., Chum, M., Chiò, A., Sobue, G., Aoki, M., Yoshino, H., Doyu, M., Selness, D., Todorovic, V., Hirai, M., Sasson, N., Takahashi, F., Cecić, M., Wamil, A., & Apple, S. (2026). Phase 3b Extension Study MT ‐1186‐ A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis. Muscle & Nerve. https://doi.org/10.1002/mus.70120

Vancouver

Genge A, Rothstein J, De Silva S, Zinman L, Chum M, Chiò A, et al. Phase 3b Extension Study MT ‐1186‐ A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis. Muscle & Nerve. 2026. doi:10.1002/mus.70120

BibTeX
@article{Genge2026,
  author = {Genge, Angela and Rothstein, Jeffrey and De Silva, Shari and Zinman, Lorne and Chum, Marvin and Chiò, Adriano and Sobue, Gen and Aoki, Masashi and Yoshino, Hiide and Doyu, Manabu and Selness, Daniel and Todorovic, Vesna and Hirai, Manabu and Sasson, Nissim and Takahashi, Fumihiro and Cecić, Michelle and Wamil, Art and Apple, Stephen},
  title = {Phase 3b Extension Study MT ‐1186‐ A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70120}
}
Kostenlos starten →